GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » ROE % Adjusted to Book Value

Vidac Pharma Holding (STU:T9G) ROE % Adjusted to Book Value : 0.00% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding ROE % Adjusted to Book Value?

Vidac Pharma Holding's ROE % for the quarter that ended in Jun. 2024 was 0.00%. Vidac Pharma Holding's PB Ratio for the quarter that ended in Jun. 2024 was N/A. Vidac Pharma Holding's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was N/A.

Vidac Pharma Holding ROE % Adjusted to Book Value Historical Data

The historical data trend for Vidac Pharma Holding's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding ROE % Adjusted to Book Value Chart

Vidac Pharma Holding Annual Data
Trend Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - -

Vidac Pharma Holding Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value - - - - -

Competitive Comparison of Vidac Pharma Holding's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Vidac Pharma Holding's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vidac Pharma Holding's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vidac Pharma Holding's ROE % Adjusted to Book Value falls into.


Vidac Pharma Holding ROE % Adjusted to Book Value Calculation

Vidac Pharma Holding's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Vidac Pharma Holding's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Vidac Pharma Holding Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
Traded in Other Exchanges
N/A
Address
Wenlock Road, 20-22, London, GBR, N1 7GU
Website
https://www.vidacpharma.com
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines